Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$2.67 +8.1%	$2.21	$1.47 ▼ $17.31	$65.22M	N/A	231,582 shs	58,593 shs
ATRA Atara Biotherapeutics	$12.13 +5.1%	$9.62	$5.01 ▼ $18.70	$72.30M	0.26	113,466 shs	57,451 shs
HOTH Hoth Therapeutics	$1.30 +2.4%	$1.29	$0.59 ▼ $3.80	$17.17M	0.66	4.13 million shs	408,313 shs
QNTM Quantum Biopharma	$23.10 -5.1%	$21.93	$2.70 ▼ $38.25	$67.22M	0.71	1.26 million shs	234,062 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	-3.52%	-19.81%	+21.08%	+36.46%	-77.99%
ATRA Atara Biotherapeutics	+11.82%	+2.85%	+25.03%	+74.58%	+48.52%
HOTH Hoth Therapeutics	+9.48%	-7.97%	-11.81%	+45.98%	+103.53%
QNTM Quantum Biopharma	-7.35%	-0.98%	+30.25%	+195.99%	+2,432,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARTV Artiva Biotherapeutics	2.6802 of 5 stars	3.5	0.0	0.0	0.0	2.2	1.7	1.3
ATRA Atara Biotherapeutics	4.2685 of 5 stars	3.4	1.0	0.0	4.7	2.8	3.3	0.6
HOTH Hoth Therapeutics	2.9451 of 5 stars	3.6	5.0	0.0	0.0	2.6	0.0	0.6
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTV Artiva Biotherapeutics	3.00	Buy	$17.00	536.70% Upside
ATRA Atara Biotherapeutics	2.83	Moderate Buy	$20.00	64.88% Upside
HOTH Hoth Therapeutics	3.25	Buy	$4.00	207.69% Upside
QNTM Quantum Biopharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest HOTH, ARTV, QNTM, and ATRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/30/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/23/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/26/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/18/2025	QNTM Quantum Biopharma	Singular Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Moderate Buy
6/12/2025	HOTH Hoth Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/11/2025	ARTV Artiva Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$12.00
5/15/2025	ARTV Artiva Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $18.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	$6.10 per share	N/A
ATRA Atara Biotherapeutics	$128.94M	0.56	N/A	N/A	($16.89) per share	-0.72
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	$0.86 per share	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	$0.70 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTV Artiva Biotherapeutics	-$65.37M	N/A	0.00	N/A	N/A	N/A	-42.60%	-37.76%	N/A
ATRA Atara Biotherapeutics	-$85.40M	-$3.72	N/A	N/A	N/A	3.07%	-7.16%	5.54%	N/A
HOTH Hoth Therapeutics	-$8.19M	-$1.07	N/A	N/A	N/A	N/A	-109.18%	-100.22%	N/A
QNTM Quantum Biopharma	-$14.20M	-$14.02	N/A	N/A	N/A	N/A	-270.22%	-131.87%	8/13/2025 (Estimated)

Latest HOTH, ARTV, QNTM, and ATRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	HOTH Hoth Therapeutics	-$0.27	-$0.17	+$0.10	-$0.17	N/A	N/A
8/11/2025	Q2 2025	ATRA Atara Biotherapeutics	-$0.32	$0.19	+$0.51	$0.19	$4.23 million	$17.58 million
8/6/2025	Q2 2025	ARTV Artiva Biotherapeutics	-$0.84	-$0.87	-$0.03	-$0.87	N/A	N/A
8/6/2025	Q2 2025	QNTM Quantum Biopharma	-$0.17	-$3.23	-$3.06	-$3.23	$2.89 million	N/A
5/15/2025	Q1 2025	ATRA Atara Biotherapeutics	-$3.07	$3.50	+$6.57	$3.50	$4.30 million	$98.10 million
5/14/2025	Q1 2025	QNTM Quantum Biopharma	-$0.37	-$1.41	-$1.04	-$3.53	$2.09 million	$2.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
ATRA Atara Biotherapeutics	N/A	N/A	N/A	N/A	N/A
HOTH Hoth Therapeutics	N/A	N/A	N/A	N/A	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTV Artiva Biotherapeutics	N/A	13.84	13.84
ATRA Atara Biotherapeutics	N/A	0.57	0.57
HOTH Hoth Therapeutics	N/A	15.09	15.08
QNTM Quantum Biopharma	N/A	0.78	0.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTV Artiva Biotherapeutics	N/A
ATRA Atara Biotherapeutics	70.90%
HOTH Hoth Therapeutics	7.08%
QNTM Quantum Biopharma	1.24%

Insider Ownership

Company	Insider Ownership
ARTV Artiva Biotherapeutics	21.40%
ATRA Atara Biotherapeutics	4.00%
HOTH Hoth Therapeutics	6.92%
QNTM Quantum Biopharma	8.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTV Artiva Biotherapeutics	81	24.43 million	19.20 million	N/A
ATRA Atara Biotherapeutics	330	5.96 million	5.72 million	Optionable
HOTH Hoth Therapeutics	4	13.21 million	12.30 million	Not Optionable
QNTM Quantum Biopharma	N/A	2.91 million	2.66 million	N/A

HOTH, ARTV, QNTM, and ATRA Headlines

Recent News About These Companies

Quantum BioPharma Announces Update to Previously Announced Private Placement

August 11 at 6:32 PM | newsfilecorp.comN

Why Is Quantum BioPharma In The News Today? Here’s An Important Update On Its Multiple Sclerosis Investigational Drug

August 11 at 9:19 AM | msn.com

Quantum BioPharma Signs Agreement to Manufacture Oral Drug Formulation of its Potential Breakthrough Drug Lucid-21-302 (Lucid-MS) for Use in its Upcoming Phase 2 Multiple Sclerosis Trial

August 11 at 7:40 AM | globenewswire.com

Quantum BioPharma Reports Positive Phase 1 Results for MS Drug Lucid-MS

August 9, 2025 | theglobeandmail.com

Quantum BioPharma Pursues Legal Action Over Alleged Stock Manipulation

August 9, 2025 | theglobeandmail.com

Quantum BioPharma Announces Very Promising Results from the Massachusetts General Hospital Scientists on the Novel Positron Emission Tomography (PET) Tracer Used to Detect and Monitor Demyelination in Multiple Sclerosis Patients

August 8, 2025 | globenewswire.com

Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt

August 7, 2025 | globenewswire.com

Quantum Biopharma (QNTM) to Release Earnings on Wednesday

August 7, 2025 | marketbeat.com

Quantum BioPharma stock falls after clinical trial report release

August 5, 2025 | investing.com

Quantum Biopharma Announces Positive Results of the Clinical Study Report (CSR) for the Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of Experimental Multiple Sclerosis Drug Lucid-21-302 (Lucid-MS)

August 5, 2025 | globenewswire.com

Quantum BioPharma Files Reply and Provides Update on Court Case Seeking Damages Against CIBC, RBC and Others in Excess of $700,000,000 USD for Possible Stock Price Manipulation/Spoofing

August 4, 2025 | globenewswire.com

Quantum BioPharma Licensee Unbuzzd Wellness Inc. Commences Reg D Capital Raise Campaign to Fund Growth and Possible IPO

July 31, 2025 | globenewswire.com

Quantum BioPharma Makes Strategic Investment in GameStop

July 24, 2025 | theglobeandmail.com

Quantum BioPharma purchases 2,000 shares of GameStop

July 22, 2025 | msn.com

Quantum BioPharma stock falls after GameStop share purchase

July 22, 2025 | investing.com

Quantum Biopharma (NASDAQ:QNTM) Shares Up 3.8% - Still a Buy?

July 19, 2025 | marketbeat.com

Quantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United Kingdom - Morningstar

July 9, 2025 | morningstar.comM

Quantum BioPharma Ltd. (QNTM) - Yahoo Finance

July 9, 2025 | finance.yahoo.com

Quantum BioPharma Submits its Candidate Breakthrough Patented Drug for Multiple Sclerosis for Fast-Track Program in the United Kingdom

July 8, 2025 | finance.yahoo.com

QNTM - Quantum BioPharma Ltd Ordinary Shares - Morningstar

July 3, 2025 | morningstar.comM

Quantum BioPharma Announces Private Placement - The Manila Times

June 29, 2025 | manilatimes.netM

New MarketBeat Followers Over Time

Media Sentiment Over Time

HOTH, ARTV, QNTM, and ATRA Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

$2.67 +0.20 (+8.10%)

Closing price 04:00 PM Eastern

Extended Trading

$2.66 -0.02 (-0.56%)

As of 04:10 PM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Atara Biotherapeutics NASDAQ:ATRA

$12.13 +0.59 (+5.11%)

Closing price 04:00 PM Eastern

Extended Trading

$12.04 -0.09 (-0.70%)

As of 04:10 PM Eastern

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.

Hoth Therapeutics NASDAQ:HOTH

$1.30 +0.03 (+2.36%)

Closing price 04:00 PM Eastern

Extended Trading

$1.28 -0.02 (-1.15%)

As of 04:21 PM Eastern

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.

Quantum Biopharma NASDAQ:QNTM

$23.10 -1.23 (-5.06%)

Closing price 03:58 PM Eastern

Extended Trading

$23.33 +0.23 (+1.00%)

As of 04:19 PM Eastern

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time